Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 5 Carcinoma, Non-Small-Cell Lung 4 Neuroblastoma 2 Neoplasms 2 Lymphoma, Large-Cell, Anaplastic 2 Lung Neoplasms 2 Glioblastoma 2 Recurrence 1 Lymphoma 1 Glioma 1 Diffuse Intrinsic Pontine Glioma 1 Colorectal Neoplasms 1 Castration-resistant Prostate Cancer 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Breast Neoplasms 1 Advanced Cancers 1 Advanced Cancer 1 Adenocarcinoma 1

Interventions

Fluorouracil 71 pembrolizumab 62 Bevacizumab 60 Oxaliplatin 59 Cetuximab 59 Leucovorin 56 Irinotecan 55 Capecitabine 31 Nivolumab 23 Gemcitabine 18 Folfox protocol 18 Cisplatin 18 IFL protocol 17 Cyclophosphamide 16 Carboplatin 15 atezolizumab 14 Specimen Handling 14 Paclitaxel 14 Magnetic Resonance Spectroscopy 14 Biopsy 14 trifluridine tipiracil drug combination 12 Pemetrexed 10 spartalizumab 9 regorafenib 9 fludarabine 9 Panitumumab 9 130-nm albumin-bound paclitaxel 9 trametinib 8 durvalumab 8 dehydroftorafur 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Colorectal Neoplasms × Crizotinib × Clear all

NCT02510001 2021-07-13

MErCuRIC1

University of Oxford

Phase 1 Completed

82 enrolled 36 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡